相关实验视频

Updated: May 5, 2026

Selection of Plasmodium falciparum Parasites for Cytoadhesion to Human Brain Endothelial Cells

Selection of Plasmodium falciparum Parasites for Cytoadhesion to Human Brain Endothelial Cells

Published on: January 3, 2012

用共价抑制剂向CLK3:用于疟疾治疗的新策略

Skye B Brettell¹, Omar Janha², Abbey Begen³

¹School of Chemistry, The Advanced Research Centre, University of Glasgow, 11 Chapel Lane, Glasgow G11 6EW, U.K.

Journal of medicinal chemistry

|October 23, 2024

概括

研究人员开发了一种针对疟疾寄生虫的新型共价抑制剂. 这种新的候选药物显示出高强度,长时间的作用,以及较低的耐药性,为单剂量疟疾治疗提供了潜力.

科学领域:

药用化学医学化学
寄生虫学的寄生虫学
结构生物学结构生物学

背景情况:

疟疾仍然是一个重大的全球健康负担,每年造成超过60万人的死亡.
*Plasmodium falciparum*中药物耐药性的增加需要开发具有新型作用机制的新型抗疟疾药物.

研究的目的:

设计和开发针对必不可少的疟疾激酶*Pf*CLK3.3的新型共价抑制剂.
为了确定一种潜在的化合物,用于单剂量治疗疟疾.

主要方法:

使用可逆抑制剂*Pf*CLK3的晶结构确定 (TCMDC-135051).
针对*Pf*CLK3.3中独特的氨酸残留物 (Cys368) 的共价抑制剂的设计.
在体外测试中使用重组蛋白,*P. falciparum*寄生虫和HepG2细胞来评估功效,选择性和耐药性.

主要成果:

乙胺化合物4证明了纳米分子效能和对*Pf*CLK3.3的共价抑制.
化合物4在冲洗后对寄生虫表现出持续的疗效,这表明作用时间长.
化合物4显示出改善的激酶选择性,对HepG2细胞的高选择性指数,以及对抗性的低倾向 (日志MIR>8.1).

结论:

化合物4是第一个发现的疟疾激酶 (*Pf*CLK3) 的共价抑制剂.
这种新型的共价抑制剂显示出一种新的抗疟疾疗法的有前途特征.
这些发现支持化合物4作为开发单剂量疟疾治愈药物的潜在头.

更多相关视频

CRISPR/Cas9 Gene Editing to Make Conditional Mutants of Human Malaria Parasite P. falciparum

CRISPR/Cas9 Gene Editing to Make Conditional Mutants of Human Malaria Parasite P. falciparum

Published on: September 18, 2018

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Anthelminthic Agents

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...